title: Clinical trial: a randomized trial of pegylated-interferon-alpha-2a plus ribavirin with or without amantadine in treatment-naïve or relapsing chronic hepatitis C patients.
abstract: BACKGROUND
  The combination therapy of pegylated-interferon-alpha2a plus ribavirin is considered as the standard of care for patients with chronic hepatitis C. A sustained viral response is obtained in 40-50% of naïve patients with genotype 1 and in around 80% of naïve patients with genotype 2 or 3.
  
  
  OBJECTIVE
  To assess whether amantadine, added to the conventional combination therapy, could improve the treatment efficacy.
  
  
  METHODS
  In all, 630 patients (intent-to-treat population) with chronic hepatitis C were randomized into two groups: 316 patients (treatment group) received pegylated-interferon-alpha2a (180 microg once weekly) plus ribavirin (1000-1200 mg/daily) with amantadine (200 mg/daily); 314 patients (control group) received pegylated-interferon-alpha2a (180 microg once weekly) plus ribavirin (1000-1200 mg/daily) without amantadine. The duration of the treatment was 48 weeks for genotypes 1, 4, 5 and 6, and 24 weeks for genotypes 2 and 3.
  
  
  RESULTS
  There was no statistically significant difference between treatments groups for any of the variables tested for. Subgroups of patients likely to take advantage of the addition of amantadine were not identified.
  
  
  CONCLUSIONS
  This large study definitely excludes the role of amantadine in addition of conventional combination therapy in the treatment of chronic hepatitis C patients.
authors.affiliation: CHU Brugmann, Brussels, Belgium. philippe.langlet@chu-brugmann.be
authors.forename: P
authors.initials: P
authors.lastname: Langlet
authors.forename: F
authors.initials: F
authors.lastname: D'Heygere
authors.forename: J
authors.initials: J
authors.lastname: Henrion
authors.forename: M
authors.initials: M
authors.lastname: Adler
authors.forename: J
authors.initials: J
authors.lastname: Delwaide
authors.forename: H
authors.initials: H
authors.lastname: Van Vlierberghe
authors.forename: J P
authors.initials: JP
authors.lastname: Mulkay
authors.forename: L
authors.initials: L
authors.lastname: Lasser
authors.forename: R
authors.initials: R
authors.lastname: Brenard
authors.forename: Y
authors.initials: Y
authors.lastname: Horsmans
authors.forename: P
authors.initials: P
authors.lastname: Michielsen
authors.forename: A
authors.initials: A
authors.lastname: Laureys
authors.forename: F
authors.initials: F
authors.lastname: Nevens
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000547:Amantadine / Q000008:administration & dosage; D000998:Antiviral Agents / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D011994:Recombinant Proteins; D012044:Regression Analysis; D012254:Ribavirin / Q000008:administration & dosage*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D000547:Amantadine; C100416:peginterferon alfa-2a